Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
Unless the context otherwise requires, references in this Form 10-K to the "company," "Versartis," "we," "us" and "our" refer to Versartis, Inc. Overview Versartis, Inc. (the "Company" "We" "Our") is an endocrine-focused biopharmaceutical company initially developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor compliance, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown to more than $3 billion in 2014. Based on market research, we believe that the market for daily rhGH products can continue to grow up to $4 billion following the launch of long-acting rhGH therapies. ... More ...
Where does VSAR fit in the risk graph?
|Annual EPS Est:||$-2.84|
|Quarterly EPS Est:||-0.78|